Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016', provides in depth analysis on Trans-Activator Of Transcription (Tat) targeted pipeline therapeutics. The report provides comprehensive information on the Trans-Activator Of Transcription (Tat), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Trans-Activator Of Transcription (Tat) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Trans-Activator Of Transcription (Tat) - The report reviews Trans-Activator Of Transcription (Tat) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Trans-Activator Of Transcription (Tat) targeted therapeutics and enlists all their major and minor projects - The report assesses Trans-Activator Of Transcription (Tat) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Trans-Activator Of Transcription (Tat) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Trans-Activator Of Transcription (Tat) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Trans-Activator Of Transcription (Tat) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Trans-Activator Of Transcription (Tat) Overview 6 Therapeutics Development 7 Trans-Activator Of Transcription (Tat) - Products under Development by Stage of Development 7 Trans-Activator Of Transcription (Tat) - Products under Development by Therapy Area 8 Trans-Activator Of Transcription (Tat) - Products under Development by Indication 9 Trans-Activator Of Transcription (Tat) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Trans-Activator Of Transcription (Tat) - Products under Development by Companies 12 Trans-Activator Of Transcription (Tat) - Products under Development by Universities/Institutes 14 Trans-Activator Of Transcription (Tat) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Trans-Activator Of Transcription (Tat) - Companies Involved in Therapeutics Development 22 Akshaya Bio Inc. 22 Biosantech SA 23 Trans-Activator Of Transcription (Tat) - Drug Profiles 24 CSTATI-1 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 HIV vaccine - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 HIV vaccine - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 HIV vaccine - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 HIV-1 vaccine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Recombinant Protein to Inhibit Tat and Rev for HIV-1 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Trans-Activator Of Transcription (Tat) - Dormant Projects 33 Trans-Activator Of Transcription (Tat) - Discontinued Products 34 Trans-Activator Of Transcription (Tat) - Featured News & Press Releases 35 Jun 08, 2016: Improving the Effect of HIV Drugs by Use of the Tat Vaccine 35 Mar 15, 2016: Publication in Retrovirology of the results of Biosantech's phase IIA clinical trial for the anti-HIV candidate vaccine 36 Jul 29, 2015: Cannabis Science Signs Gary Blick, MD and Proceeds With CS-TATI-1 for HIV and Kaposi Sarcoma Drug Development Program 36 Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests 37 Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I 38 Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma 39 Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi's Sarcoma 40 Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Akshaya Bio Inc., H1 2016 22 Pipeline by Biosantech SA, H1 2016 23 Dormant Projects, H1 2016 33 Discontinued Products, H1 2016 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.